GlobeNewswire

ObsEva Reports New Clinical Evidence of Nolasiban Mechanism of Action, Supporting Its Potential to Increase Live Birth Rate Following Embryo Transfer in IVF

Share

Results show decreased uterine contractions, increased endometrial blood flow and gene expression relevant for uterine receptivity to implantation

4Q:19 Read-out confirmed for Phase 3 IMPLANT 4 trial of ObsEva’s novel oxytocin receptor antagonist nolasiban


Geneva, Switzerland and Boston, MA – September 03, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today reported results from a mechanism of action (MoA) trial of its oral oxytocin receptor antagonist, nolasiban. The trial assessed the effect of nolasiban on uterine contractions and endometrial blood flow, both of which are known to be associated with uterine receptivity and embryo implantation, and ultimately pregnancy and live birth following IVF.  The effect of nolasiban administration on endometrial gene expression was also investigated.

The randomized, double blind trial  was  conducted in 42 healthy female volunteers, aged 18 to 37 years, who had been pre-treated with a hormonal preparation identical to that used in women undergoing frozen-thawed embryo transfer.  On the day corresponding to a Day 5 embryo transfer, subjects received a single, oral administration of the clinical dose of 900 mg nolasiban, a supra-therapeutic dose of 1800 mg nolasiban, or matching placebo. Pharmacodynamic (PD) assessments up to 24 hours after treatment included measurements of uterine contraction frequency by ultrasound and uterine perfusion by 3D-power Doppler. Endometrial biopsy was obtained following PD assessments, and tissue samples analyzed for differential mRNA expression.

A single oral dose of nolasiban produced measurable and durable effects, with a reduction in the frequency of uterine contractions and a marked and sustained increase in endometrial blood flow.  Within 24 hours of nolasiban administration, statistically significant changes were observed in the expression of a set of endometrial genes that have been described as potentially important in endometrial receptivity and embryonic implantation.

These nolasiban trial results represent the first in vivo demonstration of the effect of oxytocin receptor inhibition on endometrial blood flow and receptivity-related gene expression.  These important new MoA findings support the potential for nolasiban to increase live birth rates following IVF.  The trial results are scheduled to be presented at an upcoming international OB/GYN conference.

“These highly unique and informative new data substantially expand our understanding of the potential mechanism of action of nolasiban in increasing the success of embryo implantation, a critical process in the achievement of pregnancy following IVF, which has not seen significant advances despite other notable achievements in the field. We are extremely pleased to have observed the positive effects of nolasiban in reducing uterine contraction frequency, increasing endometrial blood flow, and driving specific changes in gene expression, which all support the potential to increase live birth rates following embryo transfer.  These data are timely as we look forward to the upcoming results of our second  nolasiban phase 3 trial, IMPLANT 4, and a submission of a Marketing Authorization Application (MAA) in Europe expected by the end of this year,” said Ernest Loumaye, CEO and co-Founder of ObsEva.


About Assisted Reproductive Technology (ART)

Infertility affects approximately 10% of reproductive-aged couples, with more than 2 million ART treatments (including IVF and ICSI) performed worldwide each year. Currently in the United States, 62% of fresh embryo transfers are performed on Day 5 and 30% on Day 3 (CDC report, 2016 data).

While the success of ART depends on multiple factors such as embryo quality and ET procedures, successful embryo implantation and subsequent pregnancy ultimately hinge on endometrial receptivity, which may be reduced by excessive uterine contractions and suboptimal blood flow to the uterus at the time of embryo transfer.


About Nolasiban

Nolasiban (previously known as OBE001), is an oral oxytocin receptor antagonist which has been shown in an IMPLANT2 phase 3 trial to increase ongoing pregnancy rate and live birth rate  in patients undergoing single embryo transfer. ObsEva licensed nolasiban from Merck KGaA, Darmstadt, Germany, in 2013 and retains worldwide, exclusive, commercial rights.


About ObsEva

ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving IVF outcomes. ObsEva is listed on the NASDAQ Global Select Market and is trading under the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com .


Cautionary Note Regarding Forward Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe", "expect", "may", "plan," "potential," "will," and similar expressions, and are based on ObsEva’s current beliefs and expectations. These forward-looking statements include statements regarding the potential for nolasiban to increase live birth rates following embryo transfer, expectations regarding the clinical development of nolasiban, data from clinical trials and the Company’s regulatory plans regarding nolasiban. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials and clinical development and related regulatory reviews and approvals, including the risk that the results of earlier clinical trials may not be predictive of the results of later-stage clinical trials, ObsEva’s reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in the Risk Factors section of ObsEva’s Annual Report on Form 20-F for the year ended December 31, 2018, and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEva’s website at http://www.obseva.com . Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.


For further information, please contact:


Media Contact Switzerland and Europe:
Christophe Lamps
Dynamics Group
cla@dynamicsgroup.ch
+41 22 308 6220 Office
+41 79 476 26 87 Mobile


Media Contact U.S.:
Marion Janic
RooneyPartners LLC
mjanic@rooneyco.com
+1 212 223 4047 Office
+1 646 537 5649 Mobile


CEO Office Contact:
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550


Investor Contact:
Mario Corso
Senior Director, Investor Relations
mario.corso@obseva.com
+1 857 972 9347 Office
+1 781 366 5726 Mobile

###



Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

KALLELSE TILL ÅRSSTÄMMA I HOYLU AB (PUBL)26.5.2020 22:30:00 CESTPressemelding

KALLELSE TILL ÅRSSTÄMMA I HOYLU AB (PUBL) Aktieägarna i Hoylu AB (publ), org. nr 559084-6381 ("Bolaget") kallas härmed till Bolagets årsstämma torsdagen den 25 juni 2020, kl. 09.00 hos Eversheds Sutherland Advokatbyrå på Strandvägen 1 i Stockholm. Inregistrering inleds kl. 08.45. INFORMATION MED ANLEDNING AV COVID-19 Med anledning av COVID-19 kommer Bolaget att vidta vissa försiktighetsåtgärder inför årsstämman. För att minska risken för smittspridning kommer ingen förtäring eller dryck att erbjudas. Styrelsemedlemmar och Bolagets ledning kommer i möjligaste mån att närvara via elektronisk uppkoppling. Aktieägarna har möjlighet att närvara via ombud. DELTAGANDE En aktieägare som vill delta på årsstämman ska: vara införd i den av Euroclear Sweden AB förda aktieboken senast torsdagen den 18 juni 2020, och anmäla sitt deltagande senast torsdagen den 18 juni 2020, helst före kl. 16.00. Anmälan att delta på årsstämman ska ske via e-post till bolagsstamma@hoylu.com, via post till to Hoylu AB

NOTICE TO ATTEND THE ANNUAL GENERAL MEETING OF HOYLU AB (PUBL)26.5.2020 22:30:00 CESTPress release

N.B. This English text is an unofficial translation of the Swedish original of the notice to attend the Annual General Meeting in Hoylu AB (publ), and in case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. NOTICE TO ATTEND THE ANNUAL GENERAL MEETING OF HOYLU AB (PUBL) The shareholders of Hoylu AB (publ), reg. no 559084-6381 (the “Company”) are hereby summoned to attend the annual general meeting held at 09:00 (CEST) on Thursday 25 June 2020 at the premises of Eversheds Sutherland Advokatbyrå located at Strandvägen 1, Stockholm, Sweden. Registration begins at 08.45 (CEST). INFORMATION RELATED TO THE CORONA VIRUS To minimise the risk of spreading the corona virus, no food and beverages will be served at the AGM. Participation of board members and company management will be restricted to online where possible. Shareholders who so desire can attend via a representative. NOTIFICATION OF PARTICIPATION ETC. Shareholders who wish to a

Results of the annual general meeting of ENR Russia Invest SA26.5.2020 19:10:00 CESTPress release

Press Release Geneva, 26 May 2020 Results of the annual general meeting of ENR Russia Invest SA All resolutions proposed by the board of directors (“Board”) of ENR Russia Invest SA (“Company”) were unanimously approved at the Company’s annual general meeting held on 26 May 2020, being: Approval of 2019 annual report and financial statements for the year ended 31 December 2019 of both the group and the Company and the carrying forward of CHF 234'656 of retained losses.Discharge of all members of the Board for the 2019 financial year.Re-election for one year of Dr. Walter Fetscherin and Mr. Gustav Stenbolt to the Board, with Mr. Gustav Stenbolt as Company chairman (each for a term of office up to the next annual general meeting).Election of Dr. Walter Fetscherin and Mr. Gustav Stenbolt to the Company’s remuneration committee.Election of ZELLWEGER & MASSROURI as independent shareholder representative for the 2021 annual general meeting.Re-election of BDO SA, Geneve as the Company and grou

Saniona meddelar utfall i optionsinlösen26.5.2020 18:15:00 CESTPressemelding

PRESSMEDDELANDE 26 maj 2020 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, meddelade idag utfallet i inlösen av teckningsoptioner av serie TO 1, vilka emitterades i samband med Sanionas företrädesemission och riktade emission under det första kvartalet 2020. Under perioden 11 – 25 maj 2020 har innehavare av teckningsoptioner av serie TO 1 kunnat teckna aktier med stöd av teckningsoptioner. Totalt nyttjades 970 797 teckningsoptioner av serie TO 1, vilket motsvarar en nyttjandegrad om 65,61 procent. Saniona tillförs därmed cirka 24,3 MSEK före emissionskostnader, vilka beräknas uppgå till cirka 0,4 MSEK. Antal aktier och aktiekapital Saniona tillförs cirka 24,3 MSEK före emissionskostnader. Emissionskostnaderna beräknas uppgå till cirka 0,4 MSEK. När de nya aktierna har registrerats hos Bolagsverket kommer antalet aktier i Saniona uppgå till 30 383 316 stycken och aktiekapitalet uppgå till 1 519 165,80 SEK. ”Vi är tacksamma fö

Saniona announces outcome of warrant exercise26.5.2020 18:15:00 CESTPress release

PRESS RELEASE May 26, 2020 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, announced today the outcome in the exercise of warrants of series TO 1, that was issued in connection with Saniona’s rights issue and directed issue in the first quarter of 2020. During the period May 11th – 25th, 2020, holders of warrants of series TO 1 had the right to subscribe for new shares, by exercise of warrants. In total, 970,797 warrants of series TO 1 were exercised, corresponding to a subscription rate of 65.61 percent. Saniona will thereby receive proceeds of approx. SEK 24.3 million, before issue costs, which amount to approx. SEK 0.4 million. Number of shares and share capital Saniona will receive proceeds of approx. SEK 24.3 million, before issue costs. Issue costs amount to approx. SEK 0.4 million. When the new shares have been registered with the Swedish Companies Registration Office (“Bolagsverket”), the total number of shares in Saniona will amount

Intervest Offices & Warehouses: Result of the optional dividend in shares for financial year 201926.5.2020 18:00:00 CESTPress release

Shareholders opted for 61,6% of the shares for the optional dividendShareholders’ equity strengthened by € 16,3 million The shareholders of regulated real estate company Intervest Offices & Warehouses opted for 61,6% of their shares entitled to dividend for a contribution of their dividend rights in return for new shares instead of payment of the dividend in cash. Attachment Result optional dividend